A high-loading and cycle-stable solid-phase conversion sulfur cathode using edible fungus slag-derived microporous carbon as sulfur host

Developing a high sulfur(S)-loading cathode with high capacity utilization and long term cyclability is a key challenge for commercial implementation of Li-S battery technology.To overcome this challenge,we propose a solid-phase conversion sulfur cathode by using an edible fungus slag-derived porous carbon(CFS)as sulfur host to fabricate the S/CFS composite and meanwhile,utilizing the vinyl carbonate(VC)as co-solvent of the ether-based electrolyte to in-situ form a protective layer on the S/CFS composite surface through its nucleophilic reaction with the freshly generated lithium polysulfides(LiPSs)at the very beginning of initial discharge,thus isolating the interior sulfur from the outer electrolyte and inhibiting the further generation of soluble LiPSs.Benefitting from the ultrahigh specific surface area of>3,000 m^(2)·g^(−1),ideal pore size of<4 nm,and large pore volume of>2.0 cm^(3)·g^(−1)of the CFS host matrix,the S/CFS cathode even with a high S-loading of 80 wt.%(based on the weight of S/CFS composite)can still operate in a solid-phase conversion manner in the VC-ether co-solvent electrolyte to exhibit a high reversible capacity of 1,557 mAh·g^(−1),a high rate capability with 50%remaining capacity at 2 A·g^(−1)and a high cycling efficiency of 99.9%over 500 cycles.The results presented in this work suggest that a combined action of solid-phase conversion electrochemistry and nanoarchitectured host structure may provide a new path for the design and development of practical lithium-sulfur batteries.

Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia

To the Editor:The proprotein convertase subtilisin/kexin type 9(PCSK9)-inhibitor,evolocumab,can bind with PCSK9 in plasma and reduce the degradation of the PCSK9-low density lipoprotein(LDL)receptor complex,thereby reducing LDL levels.[1]In clinical practice,PCSK9 inhibitors can reduce low-density lipoprotein cholesterol(LDL-c)significantly and reduce triglycerides(TG)by about 8%to 17%.[2]We used PCSK9 inhibitors to lower blood lipids in three patients with severe hypertriglyceridemia(HTG)and performed whole-exome sequencing(WES)to analyze the genes that may contribute to hyperlipidemia in detail.We have obtained patients'consent forms.We found that PCSK9 inhibitors significantly reduced blood lipid levels,regardless of the presence of HTG mutations.These results provide new evidence for the use of PCSK9 inhibitors in the treatment of patients with severe HTG.